$30.54
0.33% yesterday
Nasdaq, Dec 30, 10:00 pm CET
ISIN
US40131M1099
Symbol
GH

Guardant Health, Inc. Target price 2024 - Analyst rating & recommendation

Guardant Health, Inc. Classifications & Recommendation:

Buy
92%
Hold
4%
Sell
4%

Guardant Health, Inc. Price Target

Target Price $41.80
Price $30.54
Potential
Number of Estimates 20
20 Analysts have issued a price target Guardant Health, Inc. 2025 . The average Guardant Health, Inc. target price is $41.80. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 24 analysts: 22 Analysts recommend Guardant Health, Inc. to buy, 1 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Guardant Health, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Guardant Health, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 563.95 723.90
25.45% 28.36%
EBITDA Margin -92.14% -33.15%
16.98% 64.02%
Net Margin -93.47% -58.65%
46.78% 37.25%

22 Analysts have issued a sales forecast Guardant Health, Inc. 2024 . The average Guardant Health, Inc. sales estimate is

$724m
Unlock
. This is
4.57% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$727m 5.05%
Unlock
, the lowest is
$722m 4.25%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $564m 25.45%
2024
$724m 28.36%
Unlock
2025
$843m 16.49%
Unlock
2026
$1.0b 20.37%
Unlock
2027
$1.2b 20.90%
Unlock
2028
$1.4b 16.35%
Unlock

14 Analysts have issued an Guardant Health, Inc. EBITDA forecast 2024. The average Guardant Health, Inc. EBITDA estimate is

$-240m
Unlock
. This is
49.15% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-229m 51.50%
Unlock
, the lowest is
$-249m 47.27%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-520m 4.15%
2024
$-240m 53.82%
Unlock
2025
$-216m 10.07%
Unlock
2026
$-176m 18.67%
Unlock
2027
$-133m 24.51%
Unlock
2028
$-111m 15.97%
Unlock

EBITDA Margin

2023 -92.14% 16.98%
2024
-33.15% 64.02%
Unlock
2025
-25.59% 22.81%
Unlock
2026
-17.29% 32.43%
Unlock
2027
-10.80% 37.54%
Unlock
2028
-7.80% 27.78%
Unlock

14 Guardant Health, Inc. Analysts have issued a net profit forecast 2024. The average Guardant Health, Inc. net profit estimate is

$-425m
Unlock
. This is
18.70% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-364m 30.36%
Unlock
, the lowest is
$-459m 12.03%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-527m 33.23%
2024
$-425m 19.46%
Unlock
2025
$-366m 13.85%
Unlock
2026
$-312m 14.63%
Unlock
2027
$-317m 1.47%
Unlock
2028
$-302m 4.68%
Unlock

Net Margin

2023 -93.47% 46.78%
2024
-58.65% 37.25%
Unlock
2025
-43.37% 26.05%
Unlock
2026
-30.76% 29.08%
Unlock
2027
-25.81% 16.09%
Unlock
2028
-21.15% 18.06%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -4.28 -3.45
33.23% 19.39%
P/E negative
EV/Sales 5.67

14 Analysts have issued a Guardant Health, Inc. forecast for earnings per share. The average Guardant Health, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.45
Unlock
. This is
18.63% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.95 30.42%
Unlock
, the lowest is
$-3.73 12.03%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-4.28 33.23%
2024
$-3.45 19.39%
Unlock
2025
$-2.97 13.91%
Unlock
2026
$-2.54 14.48%
Unlock
2027
$-2.57 1.18%
Unlock
2028
$-2.45 4.67%
Unlock

P/E ratio

Current -7.18 1.56%
2024
-8.83 22.98%
Unlock
2025
-10.25 16.08%
Unlock
2026
-12.01 17.17%
Unlock
2027
-11.83 1.50%
Unlock
2028
-12.41 4.90%
Unlock

Based on analysts' sales estimates for 2024, the Guardant Health, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.92 11.77%
2024
5.67 4.30%
Unlock
2025
4.86 14.16%
Unlock
2026
4.04 16.92%
Unlock
2027
3.34 17.29%
Unlock
2028
2.87 14.05%
Unlock

P/S ratio

Current 5.43 14.19%
2024
5.20 4.37%
Unlock
2025
4.46 14.16%
Unlock
2026
3.71 16.92%
Unlock
2027
3.06 17.29%
Unlock
2028
2.63 14.05%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today